DrugPatentWatch Database Preview

Details for Patent: 8,388,941

« Back to Dashboard

Which drugs does patent 8,388,941 protect, and when does it expire?

Patent 8,388,941 protects TRAVATAN Z and is included in one NDA.

This patent has fifteen patent family members in twelve countries.

Summary for Patent: 8,388,941

Title:	Self preserved aqueous pharmaceutical compositions
Abstract:	The use of a borate/polyol and zinc system to enhance the antimicrobial activity of multi-dose pharmaceutical compositions is described. The compositions do not require a conventional anti-microbial preservative and therefore are referred to as being `self-preserved`. The compositions possess sufficient antimicrobial activity to satisfy the preservative efficacy requirements of the USP for aqueous ophthalmic compositions.
Inventor(s):	Chowhan; Masood A. (Arlington, TX), Keith; David J. (Washington, MO)
Assignee:	Alcon Research, Ltd. (Fort Worth, TX)
Application Number:	12/441,995
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,388,941
Patent Claim Types: see list of patent claims	Composition; Use;

Drugs Protected by US Patent 8,388,941

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Novartis Pharms Corp	TRAVATAN Z	travoprost	SOLUTION/DROPS;OPHTHALMIC	021994-001	Sep 21, 2006	AT	RX	Yes	Yes			Y

Foreign Priority and PCT Information for Patent: 8,388,941

PCT Information
PCT Filed	September 20, 2007	PCT Application Number:	PCT/US2007/079094
PCT Publication Date:	April 10, 2008	PCT Publication Number:	WO2008/042619

International Family Members for US Patent 8,388,941

Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2007304996
Brazil	PI0717093
Canada	2663817
China	101522171